Eric Ruby

Safety, pharmacokinetics, and antiviral effects of ABI-H0731, a hepatitis B virus core inhibitor: a randomised, placebo-controlled phase 1 trial

Man‐Fung Yuen, Kosh Agarwal, Edward Gane et al. · ˜The œLancet. Gastroenterology & hepatology · 2019 · 107 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +13

Substituted 1,2,3,4-tetrahydroaminonaphthols: antihypertensive agents, calcium channel blockers, and adrenergic receptor blockers with catecholamine-depleting effects

Karnail S. Atwal, Brian C. O'Reilly, Eric Ruby et al. · Journal of Medicinal Chemistry · 1987 · 37 citations

Medicine, Medicinal Chemistry, Pharmacology +11

LBO-06-Interim safety and efficacy results of the ABI-H0731 phase 2a program exploring the combination of ABI-H0731 with Nuc therapy in treatment-naive and treatment-suppressed chronic hepatitis B patients

Xiaoli Ma, Jacob Lalezari, Tuan Nguyen et al. · Journal of Hepatology · 2019 · 26 citations

Medicine, Internal Medicine, Hepatology +7

Effectiveness of ravidasvir plus sofosbuvir in interferon-naïve and treated patients with chronic hepatitis C genotype-4

Gamal Esmat, Tamer Elbaz, Asmaa Gomaa et al. · Journal of Hepatology · 2017 · 23 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +14

Interim safety, tolerability pharmacokinetics, and antiviral activity of ABI-H0731, a novel core protein allosteric modulator, in healthy volunteers and non-cirrhotic viremic subjects with chronic hepatitis B

Man‐Fung Yuen, Kosh Agarwal, E. Gane et al. · Journal of Hepatology · 2018 · 13 citations

Pharmacy, Pharmacokinetics, Pharmacology +10